Table 1 Baseline clinical characteristics of patients with and without RVSD
Variables | Patients with RVSD N = 32 (71.1 %) | Patients without RVSD N = 13 (28.9 %) | p-value |
|---|---|---|---|
Age (years) | 26.1 ± 7.5 | 27.7 ± 5.4 | 0.500 |
NYHA class: | 0.809 | ||
II | 13 (40.6 %) | 6 (46.2 %) | |
III | 12 (37.5 %) | 5 (38.5 %) | |
IV | 7 (21.9 %) | 1 (7.7 %) | |
Parity ≥2 | 25 (78.9 %) | 10 (76.9 %) | 0.758 |
Breastfeeding | 30 (93.8 %) | 13 (100 %) | – |
BMI (Kg/m2) | 21.4 ± 4.6 | 21.9 ± 3.9 | 0.704 |
Systolic BP (mmHg) | 116 ± 23 | 128 ± 26 | 0.172 |
Diastolic BP (mmHg) | 83 ± 18 | 94 ± 16 | 0.051 |
Heart rate/min | 111 ± 16 | 104 ± 21 | 0.302 |
Pedal oedema | 26 (81.3 %) | 8 (61.5 %) | 0.312 |
Hepatomegaly | 19 (59.4 %) | 6 (46.2 %) | 0.515 |
Pregnancy associated hypertension | 13 (40.6 %) | 9 (69.2 %) | 0.158 |
Haemoglobin (g/dL) | 12.2 ± 1.8 | 12.9 ± 1.3 | 0.202 |
Log10 Creatinine | 2.0 ± 0.2 | 1.9 ± 0.1 | 0.020* |
Sodium (mmol/L) | 136.3 ± 6.3 | 135.5 ± 5.2 | 0.655 |
Treatment: | |||
ACEI/ARB | 15 (46.9 %) | 7 (53.9 %) | 0.749 |
Frusemide | 32 (100 %) | 13 (100 %) | – |
Spironolactone | 31 (96.9 %) | 11 (84.6 %) | 0.196 |
Digoxin | 28 (87.57 %) | 12 (92.3 %) | >0.999 |
Beta blockers | 2 (6.3 %) | 1 (7.7 %) | >0.999 |
Warfarin | 1 (3.1 %) | 1 (7.7 %) | 0.499 |
α-Methyl Dopa | 4 (12.5 %) | 2 (15.4 %) | >0.999 |